Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Sodium Chloride Injection 23.4% (120mEq/30 mL)</em>
COLUMBIA, S.C. (August 11, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Sodium Chloride Injection 23.4% (120mEq/30 mL). It is the 10th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division
Ritedose Releases Two New Single-Dose Syringe Products for Hospital Pharmacies: <em>Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL)</em>
COLUMBIA, S.C. (May 21, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL). These are part of a six-month, 12-product rollout from Ritedose for
Ritedose Brings New Unit Dose Syringe Product to the Market: <em>Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL)</em>
COLUMBIA, S.C. (May 14, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a
Ritedose Launches New Single-Dose Syringe Product: <em>Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL)</em>
COLUMBIA, S.C. (April 30, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division
Ritedose Releases Two New Single-Dose Syringe Products to the Market: <em>Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL)</em>
COLUMBIA, S.C. (April 16, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL). These are part of a 12-product rollout expected from Ritedose over the next
Ritedose Launches Two New Single-Dose Syringe Products: <em>Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) & Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL)</em>
COLUMBIA, S.C. (April 2, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) and Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL). These are part of a 12-product rollout expected from Ritedose over the
Ritedose Announces Launch of New Unit Dose Syringe Product: <em>Succinylcholine Chloride Injection 200 mg/10 mL (20 mg/mL)</em>
COLUMBIA, S.C. (March 25, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 200 mg/10 mL (20 mg/mL). It is the first of 12 Ritedose products expected to hit the market over the next six months for
Recent Comments